Vonjo to treat high-risk myelofibrosis
Drug Name: Vonjo Indications: To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets. Active Ingredient: Company: CTI BioPharma Corp. Approval Date: 2/28/2022 Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf